Crizotinib

← predicts response to

ROS1 Fusionfusion

4 source records aggregated

sensitivity

Curated

Anaplastic Large Cell Lymphoma,Inflammatory Myofibroblastic Tumor,Lung Non-Small Cell Carcinoma+1

← predicts response to

ALK Fusionfusion

9 source records aggregated

sensitivity

Curated

← predicts response to

MET Exon 14 Skipping Mutationdeletion_cna

sensitivity

Curated

← predicts response to

ROS1 Fusionfusion

sensitivity

Curated

← predicts response to

AREG Expressionexpression

resistance

Curated

Anaplastic Large Cell Lymphoma

← predicts response to

ALK Fusionfusion

sensitivity

Curated

← predicts response to

ALK Fusionfusion

13 source records aggregated

resistance

Curated

Glioblastoma,Lung Adenocarcinoma,Lung Non-Small Cell Carcinoma+3

← predicts response to

MET Amplificationamplification

9 source records aggregated

sensitivity

Curated

← predicts response to

MET Exon 14 Skipping Mutationdeletion_cna

6 source records aggregated

sensitivity

Curated

Anaplastic Large Cell Lymphoma,Diffuse Large B-Cell Lymphoma,Lung Adenocarcinoma+2

← predicts response to

ALK Fusionfusion

6 source records aggregated

sensitivity

Curated

← predicts response to

ROS1 G2032RSNV

3 source records aggregated

resistance

Curated

← predicts response to

ALK G1269ASNV

3 source records aggregated

resistance

Curated

← predicts response to

ALK C1156YSNV

3 source records aggregated

resistance

Curated

← predicts response to

ALK Fusionfusion

3 source records aggregated

sensitivity

Curated

Lung Non-Small Cell Carcinoma,Neuroblastoma

← predicts response to

ALK F1245CSNV

2 source records aggregated

resistance

Curated

← predicts response to

ALK R1275QSNV

2 source records aggregated

sensitivity

Curated

← predicts response to

ALK Amplificationamplification

2 source records aggregated

resistance

Curated

← predicts response to

ROS1 Fusionfusion

2 source records aggregated

resistance

Curated

Lung Non-Small Cell Carcinoma,Malignant Neoplasm

← predicts response to

ALK e6::e20fusion

2 source records aggregated

sensitivity

Curated

← predicts response to

MET D1228NSNV

resistance

Curated

← predicts response to

ALK I1171SSNV

resistance

Curated

← predicts response to

ALK Fusionfusion

resistance

Curated

← predicts response to

ALK I1171NSNV

resistance

Curated

← predicts response to

ALK e20::e20fusion

sensitivity

Curated

← predicts response to

NTRK1 Fusionfusion

sensitivity

Infantile Fibrosarcoma

Curated

← predicts response to

ATXN7L1 Fusionfusion

sensitivity

Curated

Malignant Head and Neck Neoplasm

← predicts response to

MET R1004GSNV

sensitivity

Curated

← predicts response to

EGFR L858RSNV

resistance

Curated

← predicts response to

ROS1 Fusionfusion

sensitivity

Curated

← predicts response to

ROS1 Fusionfusion

sensitivity

Curated

Minimally Invasive Lung Adenocarcinoma

← predicts response to

ROS1 Fusionfusion

sensitivity

Curated

← predicts response to

ALK Fusionfusion

resistance

Curated

← predicts response to

ALK G1202RSNV

resistance

Curated

Diffuse Large B-Cell Lymphoma

← predicts response to

ALK Fusionfusion

sensitivity

Curated

← predicts response to

MET Splice Site (c.3028G>A)splice

sensitivity

Curated

← predicts response to

ALK F1174LSNV

resistance

Curated

← predicts response to

ALK Fusionfusion

resistance

Curated

ALK Alternative Transcript (ATI)

← predicts response to

sensitivity

Cutaneous Melanoma

Curated

← predicts response to

ALK Fusionfusion

sensitivity

Curated

← predicts response to

ALK C1156YSNV

sensitivity

Curated

← predicts response to

ALK L1198FSNV

sensitivity

Curated

← predicts response to

ALK L1152RSNV

resistance

Curated

← predicts response to

ALK T1151dupinsertion

resistance

Curated

← predicts response to

ALK L1196MSNV

resistance

Curated

Lung Adenocarcinoma,Lung Non-Small Cell Carcinoma,Malignant Neoplasm

← predicts response to

ALK Fusionfusion

9 source records aggregated

resistance

Curated

← predicts response to

ROS1 Fusionfusion

5 source records aggregated

resistance

Curated

Anaplastic Large Cell Lymphoma,Malignant Neoplasm

← predicts response to

ALK Fusionfusion

2 source records aggregated

sensitivity

Curated

← predicts response to

ROS1 L2026MSNV

2 source records aggregated

resistance

Curated

← predicts response to

ALK Fusionfusion

2 source records aggregated

sensitivity

Curated

← predicts response to

ALK e20::e20fusion

2 source records aggregated

sensitivity

Curated

Lung Non-Small Cell Carcinoma,Malignant Colorectal Neoplasm

← predicts response to

MET Amplificationamplification

2 source records aggregated

sensitivity

Curated

Lung Non-Small Cell Carcinoma,Neuroblastoma

← predicts response to

ALK F1174LSNV

2 source records aggregated

resistance

Curated

← predicts response to

MET Overexpressionexpression

sensitivity

Curated

← predicts response to

ALK F1245CSNV

resistance

Curated

← predicts response to

ALK V1180LSNV

resistance

Curated

← predicts response to

ROS1 G2101ASNV

resistance

Curated

← predicts response to

NTRK3 G623RSNV

resistance

Curated

← predicts response to

NTRK3 Fusionfusion

resistance

Curated

← predicts response to

ABCB1 Overexpressionexpression

resistance

Curated

Malignant Colorectal Neoplasm

← predicts response to

KRAS Mutationother

sensitivity

Curated

← predicts response to

ALK I1171SNV

resistance

Curated

← predicts response to

ROS1 L2155SSNV

resistance

Curated

← predicts response to

ROS1 G2032RSNV

resistance

Curated

← predicts response to

NTRK1 Fusionfusion

sensitivity

Curated

← predicts response to

AREG Expressionexpression

resistance

Curated

← predicts response to

MET Exon 14 Skipping Mutationdeletion_cna

sensitivity

Curated

← predicts response to

ALK Amplificationamplification

resistance

Curated

← predicts response to

ALK R1275QSNV

sensitivity

Curated

← predicts response to

ALK F1174LSNV

sensitivity

Curated

← predicts response to

ALK C1156YSNV

resistance

Curated

← predicts response to

ALK S1206YSNV

resistance

Curated

← predicts response to

ALK L1196MSNV

resistance

Curated

← predicts response to

ALK G1202RSNV

resistance

Curated

Colorectal Adenocarcinoma,Malignant Breast Neoplasm

← predicts response to

ALK Fusionfusion

2 source records aggregated

sensitivity

Curated

Colorectal Adenocarcinoma

← predicts response to

ROS1 Fusionfusion

sensitivity

Curated

← predicts response to

ALK e2::e20fusion

sensitivity

Curated

Crizotinib targets …TARGETS6 of 6
→ targets	MST1R	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	ROS1	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	NPM1	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	EML4	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	ALK	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	MET	—	INHIBITOR	—	1	Curated	chembl	graph →

Crizotinib targets …TARGETS6 of 6

→ targets

MST1R

—

INHIBITOR

—

Curated

→ targets

ROS1

—

INHIBITOR

—

Curated

→ targets

NPM1

—

INHIBITOR

—

Curated

→ targets

EML4

—

INHIBITOR

—

Curated

→ targets

ALK

—

INHIBITOR

—

Curated

→ targets

MET

—

INHIBITOR

—

Curated

Crizotinib investigated for …INVESTIGATED_FOR15 of 53show all (up to 200)
→ investigated for	Lung Non-Small Cell Carcinomasubtype 7 source records aggregated	supports	A	Lung Non-Small Cell Carcinoma	7	Curated	civic	graph →
→ investigated for	Inflammatory Myofibroblastic Tumorsubtype	supports	A	Inflammatory Myofibroblastic Tumor	1	Curated	civic	graph →
→ investigated for	Anaplastic Large Cell Lymphomahematologic_malignancy	supports	A	Anaplastic Large Cell Lymphoma	1	Curated	civic	graph →
→ investigated for	Lung Non-Small Cell Carcinomasubtype 7 source records aggregated	supports	B	Lung Non-Small Cell Carcinoma	7	Curated	civic	graph →
→ investigated for	Inflammatory Myofibroblastic Tumorsubtype 2 source records aggregated	supports	B	Inflammatory Myofibroblastic Tumor	2	Curated	civic	graph →
→ investigated for	Anaplastic Large Cell Lymphomahematologic_malignancy 2 source records aggregated	supports	B	Anaplastic Large Cell Lymphoma	2	Curated	civic	graph →
→ investigated for	Malignant Neoplasmcancer_family	supports	B	Malignant Neoplasm	1	Curated	civic	graph →
→ investigated for	Neoplasmcancer_family	unknown	4	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Lung Non-Small Cell Carcinomasubtype	unknown	4	Lung Non-Small Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Lung Non-Small Cell Carcinomasubtype 22 source records aggregated	supports	C	Lung Non-Small Cell Carcinoma	22	Curated	civic	graph →
→ investigated for	Lung Adenocarcinomasubtype 16 source records aggregated	supports	C	Lung Adenocarcinoma	16	Curated	civic	graph →
→ investigated for	Neuroblastomasubtype 3 source records aggregated	supports	C	Neuroblastoma	3	Curated	civic	graph →
→ investigated for	Inflammatory Myofibroblastic Tumorsubtype 3 source records aggregated	supports	C	Inflammatory Myofibroblastic Tumor	3	Curated	civic	graph →
→ investigated for	Diffuse Large B-Cell Lymphomahematologic_malignancy 2 source records aggregated	supports	C	Diffuse Large B-Cell Lymphoma	2	Curated	civic	graph →
→ investigated for	Malignant Neoplasmcancer_family 2 source records aggregated	supports	C	Malignant Neoplasm	2	Curated	civic	graph →

Crizotinib investigated for …INVESTIGATED_FOR15 of 53show all (up to 200)

→ investigated for

7 source records aggregated

supports

Curated

→ investigated for

supports

Curated

Anaplastic Large Cell Lymphoma

→ investigated for

Anaplastic Large Cell Lymphomahematologic_malignancy

supports

Curated

→ investigated for

7 source records aggregated

supports

Curated

→ investigated for

2 source records aggregated

supports

Curated

Anaplastic Large Cell Lymphoma

→ investigated for

Anaplastic Large Cell Lymphomahematologic_malignancy

2 source records aggregated

supports

Curated

→ investigated for

Malignant Neoplasmcancer_family

supports

Curated

→ investigated for

Neoplasmcancer_family

unknown

Neoplasm

Curated

→ investigated for

unknown

Curated

→ investigated for

22 source records aggregated

supports

Curated

→ investigated for

Lung Adenocarcinomasubtype

16 source records aggregated

supports

Curated

→ investigated for

Neuroblastomasubtype

3 source records aggregated

supports

Curated

→ investigated for

3 source records aggregated

supports

Curated

Diffuse Large B-Cell Lymphoma

→ investigated for

Diffuse Large B-Cell Lymphomahematologic_malignancy

2 source records aggregated

supports

Curated

→ investigated for

Malignant Neoplasmcancer_family

2 source records aggregated

supports

Curated

Crizotinib investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 70show all (up to 200)
→ investigated in trials for	Lung Non-Small Cell Carcinomasubtype 46 trials (13 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	46	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Neoplasmcancer_family 8 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Neoplasm	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Lung Neoplasm 7 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Lung Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Solid Neoplasm 7 trials (6 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Solid Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Multiple Myeloma 6 trials (6 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Multiple Myeloma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Lymphoma 5 trials (5 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lymphoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Solid Neoplasm 5 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Solid Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Hematopoietic and Lymphoid Cell Neoplasm 4 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Hematopoietic and Lymphoid Cell Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Neoplasmcancer_family 4 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Uveal Melanoma 4 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Uveal Melanoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Anaplastic Large Cell Lymphoma, ALK-Positive 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Anaplastic Large Cell Lymphoma, ALK-Positive	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Inflammatory Myofibroblastic Tumorsubtype 3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Inflammatory Myofibroblastic Tumor	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Colorectal Neoplasm 3 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Colorectal Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Adenocarcinoma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	ALK-Positive Lung Non-Small Cell Carcinoma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	ALK-Positive Lung Non-Small Cell Carcinoma	2	Observed	clinicaltrials	graph →

Crizotinib investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 70show all (up to 200)

→ investigated in trials for

46 trials (13 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

→ investigated in trials for

Malignant Neoplasmcancer_family

8 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

→ investigated in trials for

Malignant Lung Neoplasm

7 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Lung Neoplasm

Observed

→ investigated in trials for

Malignant Solid Neoplasm

7 trials (6 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Solid Neoplasm

Observed

→ investigated in trials for

Multiple Myeloma

6 trials (6 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Multiple Myeloma

Observed

→ investigated in trials for

Lymphoma

5 trials (5 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Lymphoma

Observed

→ investigated in trials for

Solid Neoplasm

5 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Solid Neoplasm

Observed

Hematopoietic and Lymphoid Cell Neoplasm

→ investigated in trials for

4 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Hematopoietic and Lymphoid Cell Neoplasm

Observed

→ investigated in trials for

Neoplasmcancer_family

4 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Neoplasm

Observed

→ investigated in trials for

4 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

Anaplastic Large Cell Lymphoma, ALK-Positive

→ investigated in trials for

3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Anaplastic Large Cell Lymphoma, ALK-Positive

Observed

→ investigated in trials for

3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

Malignant Colorectal Neoplasm

→ investigated in trials for

3 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Colorectal Neoplasm

Observed

→ investigated in trials for

Adenocarcinoma

2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Adenocarcinoma

Observed

ALK-Positive Lung Non-Small Cell Carcinoma

→ investigated in trials for

2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

ALK-Positive Lung Non-Small Cell Carcinoma

Observed

Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma

Crizotinib studied in …STUDIED_INderived10 of 100show all (up to 200)
→ studied in	NCT02194738NA · active not recruiting Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) · 100 trials list this drug (27 active)	—	—	Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06140836Phase 3 · active not recruiting A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) · 100 trials list this drug (27 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07816380Phase 3 · not yet recruiting A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer · 100 trials list this drug (27 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04439253Phase 2 · active not recruiting Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G) · 100 trials list this drug (27 active)	—	—	Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+1	1	Observed	clinicaltrials	graph →
→ studied in	NCT04693468Phase 1 · recruiting Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial · 100 trials list this drug (27 active)	—	—	Malignant Solid Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07804186Phase 3 · recruiting Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma · 100 trials list this drug (27 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · 100 trials list this drug (27 active)	—	—	Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT03375242completed Safety and Efficacy of Xalkori ROS1 · 100 trials list this drug (27 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04603807Phase 3 · active not recruiting A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases · 100 trials list this drug (27 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02838420Phase 3 · completed A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) · 100 trials list this drug (27 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →

Crizotinib studied in …STUDIED_INderived10 of 100show all (up to 200)

→ studied in

NCT02194738NA · active not recruiting

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) · 100 trials list this drug (27 active)

—

Observed

→ studied in

NCT06140836Phase 3 · active not recruiting

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) · 100 trials list this drug (27 active)

—

Observed

→ studied in

NCT07816380Phase 3 · not yet recruiting

A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer · 100 trials list this drug (27 active)

—

Observed

Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+1

→ studied in

NCT04439253Phase 2 · active not recruiting

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G) · 100 trials list this drug (27 active)

—

Observed

→ studied in

NCT04693468Phase 1 · recruiting

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial · 100 trials list this drug (27 active)

—

Malignant Solid Neoplasm

Observed

→ studied in

NCT07804186Phase 3 · recruiting

Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma · 100 trials list this drug (27 active)

—

Observed

Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+2

→ studied in

NCT02465060Phase 2 · active not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · 100 trials list this drug (27 active)

—

Observed

→ studied in

NCT03375242completed

Safety and Efficacy of Xalkori ROS1 · 100 trials list this drug (27 active)

—

Observed

→ studied in

NCT04603807Phase 3 · active not recruiting

A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases · 100 trials list this drug (27 active)

—

Observed

→ studied in

NCT02838420Phase 3 · completed

A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) · 100 trials list this drug (27 active)

—

not mapped

Observed